M

Molecure SA
WSE:MOC

Watchlist Manager
Molecure SA
WSE:MOC
Watchlist
Price: 9.1 PLN -1.09% Market Closed
Market Cap: 183.8m PLN

EV/EBITDA
Enterprise Value to EBITDA

-6
Current
-14.7
Median
12.7
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-6
=
Enterprise Value
136.4m PLN
/
EBITDA
-22.7m PLN
EBITDA Growth EV/EBITDA to Growth
PL
M
Molecure SA
WSE:MOC
Average EV/EBITDA: 435.1
Negative Multiple: -6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
42.8
30%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13.1
7%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.7
15%
0.9
CH
Roche Holding AG
SIX:ROG
11.5
8%
1.4
UK
AstraZeneca PLC
LSE:AZN
126.9
9%
14.1
US
Merck & Co Inc
NYSE:MRK
8.9
9%
1
CH
Novartis AG
SIX:NOVN
11.5
5%
2.3
IE
E
Endo International PLC
LSE:0Y5F
267.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
8.5
3%
2.8

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-5.1
2-Years Forward
EV/EBITDA
-13.7
3-Years Forward
EV/EBITDA
-3.2